NTx™-265: rhCG, then rEPO

DRUG2 trials

Sponsors

Stem Cell Therapeutics Corp.

Conditions

Stroke

Phase 2

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

TerminatedNCT00663416

Stem Cell Therapeutics Corp.Stroke

Start: 2008-03-31End: 2009-01-31Target: 134Updated: 2009-08-12

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

WithdrawnNCT00715364

Stem Cell Therapeutics Corp.Stroke

Start: 2009-08-31End: 2010-09-30Target: 30Updated: 2011-09-05